Anagenics Limited ( (AU:AN1) ) has provided an update.
Anagenics Limited reported a significant improvement in its financial performance for the half-year ending December 2024, with a net loss reduced to $0.5 million from $2.0 million the previous year. The company underwent a successful business restructure, leading to improved cash flow and the signing of a lucrative multi-year agreement with York Street Brands. Additionally, Anagenics exited the loss-making Face MediGroup, reducing liabilities and enhancing its financial position. The transition to in-house warehousing and new ERP systems temporarily impacted sales, but growth resumed in February 2025. Product expansions and upcoming events aim to strengthen its market presence. The company is also working towards reinstating its securities on the ASX, with conditions expected to be met by April 2025.
More about Anagenics Limited
Anagenics Limited is a health, beauty, and wellness company focused on enhancing shareholder value through the global distribution and sales of its proprietary and licensed brands. The company specializes in differentiated, clinically validated anti-aging solutions, with its subsidiary BLC Cosmetics Pty Ltd dedicated to the sales and distribution of leading cosmetic and wellness products from both Australian and international brands.
Current Market Cap: A$3.69M
For detailed information about AN1 stock, go to TipRanks’ Stock Analysis page.